Hydrea

DRUG2 trials

Sponsors

Thomas Stauffer Larsen, Institut de Recherche en Sciences de la Sante

Conditions

Essential ThrombocythemiaGenetic DiseasesPolycythemia VeraPrimary Myelofibrosis

Phase 3

A Study of Low Dose Interferon Alpha Versus Hydroxyurea in Treatment of Chronic Myeloid Neoplasms

CompletedNCT01387763

Thomas Stauffer LarsenEssential Thrombocythemia, Polycythemia Vera, Primary Myelofibrosis

Start: 2012-01-31End: 2020-06-30Updated: 2022-04-27

Unknown Phase

FACA Syrup clinical trial Phase II

Active, not recruitingPACTR202603500795589

Institut de Recherche en Sciences de la SanteGenetic Diseases

Start: 2025-09-01Target: 108Updated: 2026-08-03

Related Papers

Interferon-α vs hydroxyurea in patients with myeloproliferative neoplasms (DALIAH): a multicentre, randomised, open-label, phase 3 trial in Denmark

EClinicalMedicine2026-09-09

Collagen Turnover Is Associated with Disease Severity, Bone Marrow Fibrosis, and the JAK2V617F Variant Allele Frequency in Myeloproliferative Neoplasms

Cancers2026-08-06

Circulating Extracellular Matrix Fragments As Biomarkers in Myeloproliferative Neoplasms - Baseline Data from the Daliah Trial

Blood2024-11-05

Final Analysis of the Daliah Trial: A Randomized Phase III Trial of Interferon-α Versus Hydroxyurea in Patients with MPN

Blood2023-11-029 citations

Interferon-alpha2 Treatment Reduces Circulating Neutrophil Extracellular Trap Levels in Myeloproliferative Neoplasms

Blood2022-11-15

Genomic profiling of a randomized trial of interferon-α vs hydroxyurea in MPN reveals mutation-specific responses

Blood Advances2021-09-1058 citations

Genomic Profiling of a Phase III Clinical Trial of Interferon Versus Hydroxyurea in MPN Patients Reveals Mutation-Specific and Treatment-Specific Patterns of Response

Blood2019-11-131 citations

S1609 THREE‐YEAR ANALYSIS OF THE DALIAH TRIAL ‐ A RANDOMIZED CONTROLLED PHASE III CLINICAL TRIAL COMPARING RECOMBINANT INTERFERON ALPHA‐2 VS. HYDROXYUREA IN PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS

HemaSphere2019-06-014 citations

PB2210 IMPACT OF SMOKING ON JAK2V617F ALLELE BURDEN AMONG PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS TREATED WITH PEGYLATED INTERFERON ALPHA‐2 OR HYDROXYUREA IN THE DALIAH TRIAL

HemaSphere2019-06-01

Long-Term Efficacy and Safety of Recombinant Interferon Alpha-2 Vs. Hydroxyurea in Polycythemia Vera: Preliminary Results from the Three-Year Analysis of the Daliah Trial - a Randomized Controlled Phase III Clinical Trial

Blood2018-11-2917 citations